What is HC Wainwright’s Estimate for Kyntra Bio Q3 Earnings?

Kyntra Bio Inc (NASDAQ:KYNB) – Stock analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for Kyntra Bio in a report released on Friday, August 14th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($4.31) per share for the quarter, down from their prior estimate of ($3.87). The consensus estimate for Kyntra Bio’s current full-year earnings is ($13.75) per share. HC Wainwright also issued estimates for Kyntra Bio’s Q4 2026 earnings at ($4.80) EPS, FY2026 earnings at ($2.33) EPS, FY2027 earnings at ($9.27) EPS and FY2028 earnings at ($9.21) EPS.

Other analysts have also recently issued research reports about the stock. Rodman & Renshaw started coverage on shares of Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 price target on the stock. Oppenheimer initiated coverage on shares of Kyntra Bio in a research note on Monday, July 6th. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Weiss Ratings upgraded Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kyntra Bio presently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Kyntra Bio Trading Down 3.4%

KYNB opened at $6.81 on Tuesday. The stock’s 50-day moving average price is $7.09 and its 200 day moving average price is $7.16. Kyntra Bio has a 12-month low of $6.32 and a 12-month high of $12.60. The firm has a market cap of $27.58 million, a price-to-earnings ratio of 0.15 and a beta of 1.02.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new position in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new stake in Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned 0.26% of Kyntra Bio as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 72.71% of the company’s stock.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.